EuMentis Therapeutics Plans to Initiate Phase 2 study of EM-221, a PDE10A Inhibitor, for Treatment…
Eumentis is Developing Novel Neurocircuit Selective Medicines to Treat Childhood Neurodevelopmental Disorders
NEWTON, MASSACHUSETTS, UNITED STATES, March 24, 2022 /EINPresswire.com/ -- EuMentis Therapeutics, Inc. (“EuMentis” or the…